JP2009504265A - 組織の酸化還元状態を決定するための方法 - Google Patents
組織の酸化還元状態を決定するための方法 Download PDFInfo
- Publication number
- JP2009504265A JP2009504265A JP2008526197A JP2008526197A JP2009504265A JP 2009504265 A JP2009504265 A JP 2009504265A JP 2008526197 A JP2008526197 A JP 2008526197A JP 2008526197 A JP2008526197 A JP 2008526197A JP 2009504265 A JP2009504265 A JP 2009504265A
- Authority
- JP
- Japan
- Prior art keywords
- interest
- tissue
- nitroxyl
- region
- contrast agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 239000002872 contrast media Substances 0.000 claims abstract description 90
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims abstract description 87
- 241001465754 Metazoa Species 0.000 claims abstract description 30
- 230000005291 magnetic effect Effects 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 113
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 27
- 206010021143 Hypoxia Diseases 0.000 claims description 23
- 230000001146 hypoxic effect Effects 0.000 claims description 22
- 230000005855 radiation Effects 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 229940035063 triacetoneamine-n-oxyl Drugs 0.000 claims description 6
- 238000012307 MRI technique Methods 0.000 claims description 5
- WSGDRFHJFJRSFY-UHFFFAOYSA-N 4-oxo-TEMPO Chemical group CC1(C)CC(=O)CC(C)(C)N1[O] WSGDRFHJFJRSFY-UHFFFAOYSA-N 0.000 claims description 4
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical group CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 description 102
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 37
- XNNPAWRINYCIHL-UHFFFAOYSA-N 3-carbamoyl-PROXYL Chemical compound CC1(C)CC(C(N)=O)C(C)(C)N1[O] XNNPAWRINYCIHL-UHFFFAOYSA-N 0.000 description 16
- 238000004435 EPR spectroscopy Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000013507 mapping Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 238000001983 electron spin resonance imaging Methods 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241001197446 Mus cypriacus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- -1 nitroxyl radicals Chemical class 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001950 radioprotection Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/20—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
【選択図】なし
Description
本発明は、動物組織における目的の領域の酸化還元状態を決定するための方法を提供し、該方法は、以下:a)ニトロキシル造影剤を目的の領域に投与する工程、b)該目的の領域の磁気共鳴画像を得る工程、及びc)該目的の領域中の還元されたニトロキシル造影剤の量を決定し、該目的の領域の酸化還元状態を決定する工程、を包含する。
Claims (25)
- 動物組織中の目的の領域の酸化還元状態を決定するための方法であって、以下:
a)該目的の領域にニトロキシル造影剤を投与する工程、
b)該目的の領域の磁気共鳴画像を得る工程、及び
c)該目的の領域中の還元されたニトロキシル造影剤の量を決定し、該目的の領域の該酸化還元状態を決定する工程
を包含する、方法。 - 請求項1に記載の方法であって、前記目的の領域中の前記ニトロキシル造影剤の減衰速度を決定する工程を包含する、方法。
- 請求項2に記載の方法であって、前記減衰速度が、時間の関数としての磁気共鳴画像強度の変化として計算される、方法。
- 請求項1に記載の方法であって、前記目的の領域が、正常酸素圧の組織及び低酸素の組織からなる群より選択される、方法。
- 請求項4に記載の方法であって、前記低酸素の組織が、腫瘍組織である、方法。
- 請求項4に記載の方法であって、前記正常酸素圧の組織が、前記低酸素の組織と隣接している、方法。
- 請求項1〜請求項6のいずれかに記載の方法であって、前記動物組織が、ヒト組織である、方法。
- 請求項1〜請求項7のいずれかに記載の方法であって、前記目的の領域の磁気共鳴画像を少なくとも一つ得、その後、前記ニトロキシル造影剤を、該目的の領域に投与する工程を包含する、方法。
- 請求項8に記載の方法であって、前記動物組織の酸化還元状態が、前記ニトロキシル造影剤の投与後の一以上の時点で得た磁気共鳴画像を比較することにより決定される、方法。
- 請求項9に記載の方法であって、前記磁気共鳴画像が、スポイルドグラジエントエコー(SPGR)磁気共鳴画像技術により得られる、方法。
- 請求項1に記載の方法であって、前記ニトロキシル造影剤が、3−カルバモイル−2,2,5,5−テトラメチル−1−ピロリジン−N−オキシル、3−カルボキシ−2,2,5,5−テトラメチル−1−ピロリニルオキシ、2,2,6,6−テトラメチル−4−ピペリジノール−N−オキシル、N−d16−トリアセトンアミン−N−オキシル及びトリアセトンアミン−N−オキシル並びにこれらの任意の組み合わせからなる群より選択される、方法。
- 請求項1に記載の方法であって、前記正常酸素圧の組織中の目的の領域及び低酸素の組織中の目的の領域の、磁気共鳴画像が得られ、該正常酸素圧の組織が、該低酸素の組織に隣接して位置し、かつ、該正常酸素圧の組織及び低酸素の組織の酸化還元状態が決定される、方法。
- 請求項12に記載の方法であって、前記低酸素の組織が、腫瘍組織である、方法。
- 動物組織中の目的の領域中の腫瘍を診断するための方法であって、以下:
a)ニトロキシル造影剤を、動物組織に投与する工程であって、該動物の目的の領域が、モニタリングされる、工程、
b)該目的の領域の磁気共鳴画像を得る工程、
c)目的の領域に隣接する組織の磁気共鳴画像を得る工程、
d)該目的の領域に隣接する組織中の、還元されたニトロキシル造影剤の量を決定する工程、
e)該目的の領域中の還元されたニトロキシル造影剤の量を決定し、該目的の領域に隣接する組織の酸化還元状態を、該目的の領域の酸化還元状態と比較して決定する工程、並びに
f)腫瘍が存在するかを、該目的の領域の酸化還元状態に基づいて診断する工程
を包含する、方法。 - 請求項14に記載の方法であって、前記目的の領域中のニトロキシル造影剤の減衰速度を決定する工程を包含する、方法。
- 請求項15に記載の方法であって、前記減衰速度が、時間の関数としてのMRI画像強度の変化として計算される、方法。
- 請求項16に記載の方法であって、前記目的の領域中の酸化還元状態を、該目的の領域中の前記ニトロキシル造影剤の減衰速度に基づいて決定する工程を包含する、方法。
- 請求項17に記載の方法であって、前記目的の領域の還元されたニトロキシル造影剤の量と該目的の領域に隣接する組織の還元されたニトロキシル造影剤の量との間の差異が最大になる時間を決定する工程を包含する、方法。
- 請求項14〜請求項18のいずれかに記載の方法であって、前記目的の領域が、腫瘍である、方法。
- 癌処置プロトコールを決定するための方法であって、以下:
a)ニトロキシル造影剤を、腫瘍を有する被検体に投与する工程、
b)該腫瘍の磁気共鳴画像を得る工程、
c)該腫瘍に隣接する組織の磁気共鳴画像を得る工程、
d)該腫瘍中のニトロキシル造影剤の量を決定する工程、
e)該腫瘍に隣接する組織中のニトロキシル造影剤の量を決定する工程、及び
f)該腫瘍中のニトロキシル造影剤の量と該腫瘍に隣接する組織中のニトロキシル造影剤の量とを比較して差異を決定し、放射線の線量を投与するのに適切な時間を決定する工程を包含する、方法。 - 請求項20に記載の方法であって、前記目的の領域中のニトロキシル造影剤の減衰速度を決定する工程を包含する、方法。
- 請求項21に記載の方法であって、前記減衰速度が、時間の関数としてのMRI画像強度の変化として計算される、方法。
- 請求項22に記載の方法であって、前記目的の領域の酸化還元状態を、該目的の領域中のニトロキシル造影剤の減衰速度に基づいて決定する工程を包含する、方法。
- 請求項23に記載の方法であって、前記放射線処置の線量を投与する時間が、前記腫瘍中の還元されたニトロキシル造影剤の量と該腫瘍に隣接する組織中の還元されたニトロキシル造影剤の量との差異が最大になる時であるように決定される、方法。
- 請求項24に記載の方法であって、前記ニトロキシル造影剤が、3−カルバモイル−2,2,5,5−テトラメチル−1−ピロリジン−N−オキシル、3−カルボキシ−2,2,5,5−テトラメチル−1−ピロリニルオキシ、2,2,6,6−テトラメチル−4−ピペリジノール−N−オキシル、N−d16−トリアセトンアミン−N−オキシル及びトリアセトンアミン−N−オキシル並びにこれらの任意の組み合わせからなる群より選択される、方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70751805P | 2005-08-11 | 2005-08-11 | |
PCT/US2006/031208 WO2007021847A2 (en) | 2005-08-11 | 2006-08-10 | Method for determining redox status of a tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009504265A true JP2009504265A (ja) | 2009-02-05 |
JP2009504265A5 JP2009504265A5 (ja) | 2009-09-17 |
Family
ID=37758164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008526197A Pending JP2009504265A (ja) | 2005-08-11 | 2006-08-10 | 組織の酸化還元状態を決定するための方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090028798A1 (ja) |
EP (1) | EP1912561A4 (ja) |
JP (1) | JP2009504265A (ja) |
AU (1) | AU2006279951B2 (ja) |
CA (1) | CA2617962A1 (ja) |
WO (1) | WO2007021847A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2680525A1 (en) * | 2007-03-09 | 2008-09-18 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Nitroxide radical as a treatment for neurodegeneration |
CN109313246A (zh) * | 2016-06-13 | 2019-02-05 | 国立大学法人九州大学 | 自由基消耗速度信息的获取方法以及nash的判定方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997024145A1 (fr) * | 1995-12-28 | 1997-07-10 | Daiichi Radioisotope Laboratories, Ltd. | Medicaments d'aide au diagnostic |
JP3350060B2 (ja) * | 1997-06-27 | 2002-11-25 | 株式会社第一ラジオアイソトープ研究所 | 新規なニトロキシル化合物並びにこれを有効成分とする医薬および試薬 |
JP2005034574A (ja) * | 2003-07-17 | 2005-02-10 | Shoichi Ri | 生体内酸化ストレスの評価方法 |
JP2006204551A (ja) * | 2005-01-28 | 2006-08-10 | Kyushu Univ | 生体計測装置及びその方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE249829T1 (de) * | 1990-03-16 | 2003-10-15 | Us Secretary United States Dep | Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress |
US5402785A (en) * | 1991-08-16 | 1995-04-04 | Trustees Of The University Of Penna | Methods for measuring perfusion using magnetic resonance imaging |
US6605619B1 (en) * | 1992-03-20 | 2003-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxides as protectors against oxidatives stress |
US5725839A (en) * | 1993-08-16 | 1998-03-10 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI |
US6458758B1 (en) * | 1993-08-16 | 2002-10-01 | Synzyme Technologies, Inc. | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
US5678548A (en) * | 1995-07-20 | 1997-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance |
US5828216A (en) * | 1996-08-19 | 1998-10-27 | The United States Of America As Represented By The Department Of Health And Human Services | Gated RF preamplifier for use in pulsed radiofrequency electron paramagnetic resonance and MRI |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
RU2207808C2 (ru) * | 1998-04-09 | 2003-07-10 | Амершем Хелт АС | Применение контрастных агентов в форме частиц в диагностической визуализации для изучения физиологических параметров |
US7034054B2 (en) * | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
-
2006
- 2006-08-10 EP EP06789664A patent/EP1912561A4/en not_active Withdrawn
- 2006-08-10 US US11/997,236 patent/US20090028798A1/en not_active Abandoned
- 2006-08-10 JP JP2008526197A patent/JP2009504265A/ja active Pending
- 2006-08-10 CA CA002617962A patent/CA2617962A1/en not_active Abandoned
- 2006-08-10 WO PCT/US2006/031208 patent/WO2007021847A2/en active Application Filing
- 2006-08-10 AU AU2006279951A patent/AU2006279951B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997024145A1 (fr) * | 1995-12-28 | 1997-07-10 | Daiichi Radioisotope Laboratories, Ltd. | Medicaments d'aide au diagnostic |
JP3350060B2 (ja) * | 1997-06-27 | 2002-11-25 | 株式会社第一ラジオアイソトープ研究所 | 新規なニトロキシル化合物並びにこれを有効成分とする医薬および試薬 |
JP2005034574A (ja) * | 2003-07-17 | 2005-02-10 | Shoichi Ri | 生体内酸化ストレスの評価方法 |
JP2006204551A (ja) * | 2005-01-28 | 2006-08-10 | Kyushu Univ | 生体計測装置及びその方法 |
Non-Patent Citations (6)
Title |
---|
JPN6012030953; Hsiao-Chang Chan et al.: 'Potential of albumin labeled with nitroxides as a contrast agent for magnetic resonance imaging and' Bioconjugate Chemistry Vol.1 No.1, 1990, pp.32-36 * |
JPN6012030956; Kai Chen et al.: 'Oxidation of hydroxylamines to nitroxide spin labels in living cells' Biochimica et Biophysica Acta Vol.970 No.3, 1988, pp.270-277 * |
JPN6012030961; Hideo Utsumi et al.: 'Simultaneous molecular imaging of redox reactions monitored by Overhauser-enhanced MRI with 14N- and' PNAS Vol.103 No.5, 20060131, pp.1463-1468 * |
JPN6012059272; 山田健一 他: '生体内レドックス反応の無侵襲解析を目指した融合型ESRI/MRI装置の開発' 第16回バイオメディカル分析化学シンポジウム講演要旨集 , 20030802, pp.112-113 * |
JPN6013011682; 羽柴光起: '電子スピン共鳴を放射線生物学でどのように使うか' 化学と生物 Vol.30 No.12, 1992, pp.781-787 * |
JPN6013011685; N.Devasahayam et al.: '300 MHz continuous wave electron paramagnetic resonance spectrometer for small animal in vivo imagin' REVIEW OF SCIENTIFIC INSTRUMENTS Vol.71 No.11, 2000, pp.4273-4281 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007021847A2 (en) | 2007-02-22 |
AU2006279951B2 (en) | 2013-02-14 |
EP1912561A4 (en) | 2010-12-22 |
US20090028798A1 (en) | 2009-01-29 |
WO2007021847A3 (en) | 2007-05-03 |
CA2617962A1 (en) | 2007-02-22 |
AU2006279951A1 (en) | 2007-02-22 |
EP1912561A2 (en) | 2008-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ray et al. | Tumor pH and protein concentration contribute to the signal of amide proton transfer magnetic resonance imaging | |
Ma et al. | Applying amide proton transfer‐weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas | |
Scheidegger et al. | Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3 Tesla | |
Pardoe et al. | A magnetic resonance imaging based method for measurement of tissue iron concentration in liver arterially embolized with ferrimagnetic particles designed for magnetic hyperthermia treatment of tumors | |
Musthafa et al. | Longitudinal rotating frame relaxation time measurements in infarcted mouse myocardium in vivo | |
US20140154185A1 (en) | Use of non-labeled sugars and detection by mri for assessing tissue perfusion and metabolism | |
Winter et al. | Quantitative MRI assessment of VX2 tumour oxygenation changes in response to hyperoxia and hypercapnia | |
Darkazanli et al. | On‐line monitoring of ultrasonic surgery with MR imaging | |
Stock et al. | Oxygen‐enhanced magnetic resonance ventilation imaging of the human lung at 0.2 and 1.5 T | |
Kobayashi et al. | SWIFT MRI enhances detection of breast cancer metastasis to the lung | |
Zhang et al. | Preoperative T staging of potentially resectable esophageal cancer: a comparison between free-breathing radial VIBE and breath-hold Cartesian VIBE, with Histopathological correlation | |
US20140275969A1 (en) | Functional brown adipose tissue imaging technique | |
Jones et al. | Respiration gating and Bloch fitting improve pH measurements with acidoCEST MRI in an ovarian orthotopic tumor model | |
Chung et al. | Fast T2‐weighted imaging by PSIF at 0.2 T for interventional MRI | |
Khan et al. | The follow‐up of progressive hypertrophic cardiomyopathy using magnetic resonance rotating frame relaxation times | |
JP2009504265A (ja) | 組織の酸化還元状態を決定するための方法 | |
Babsky et al. | Effect of implantation site and growth of hepatocellular carcinoma on apparent diffusion coefficient of water and sodium MRI | |
Saito et al. | Evaluation of the susceptibility artifacts and tissue injury caused by implanted microchips in dogs on 1.5 T magnetic resonance imaging | |
Larocque et al. | Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model | |
Halavaara et al. | Spin lock magnetic resonance imaging in the differentiation of hepatic haemangiomas and metastases | |
Finnerty et al. | Noninvasive quantification of oxygen saturation in the portal and hepatic veins in healthy mice and those with colorectal liver metastases using QSM MRI | |
Pavuluri et al. | Renal pH mapping using chemical exchange saturation transfer (CEST) MRI: experimental protocol | |
Fichtner et al. | In vivo 1H‐NMR microimaging with respiratory triggering for monitoring adoptive immunotherapy of metastatic mouse lymphoma | |
Park et al. | Depiction of acute stroke using 3-tesla clinical amide proton transfer imaging: saturation time optimization using an in vivo rat stroke model, and a preliminary study in human | |
Stafford et al. | Practical clinical thermometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090803 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120919 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130213 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130712 |